

Press Release

NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN THE USA, CANADA, JAPAN AND AUSTRALIA

SYGNIS AG plans to acquire profitable proteomics player Expedeon Holdings Ltd.

- **Acquisition provides well-established direct sales forces in the U.S. and Europe and broadens product portfolio**
- **Combined 2016 pro-forma revenues to exceed EUR 5 million**
- **Planned capital increase by way of a rights offering of up to 20.5 million shares**
- **New shares not subscribed will be offered to Expedeon shareholders as contribution in kind in exchange for Expedeon shares**
- **Expected proceeds of up to EUR 5 million to cover additional cash payment to Expedeon shareholders and transaction-related expenses**
- **The Company will host a conference call today at 14:00 Central European Time (CET)**

Madrid, Spain and Heidelberg, Germany, 9 May, 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today resolved, with the approval of the Supervisory Board, to acquire Expedeon Holdings Ltd., a privately held UK proteomics company with sales offices in the U.S., UK and Singapore. Expedeon develops, manufactures and commercializes proteomics reagents and tools, marketed worldwide by Expedeon's direct sales force and via distributors.

To finance the transaction, the Management Board of SYGNIS AG has resolved, with the approval of the Supervisory Board, to increase the Company's share capital by up to EUR 20,538,089.00 from EUR 16,803,891.00 to EUR 37,341,980.00 by issuing up to 20.538.089 shares by way of a rights offering.

New shares not subscribed in the rights offering will be offered to Expedeon shareholders as contribution in kind against Expedeon shares. SYGNIS intends to acquire Expedeon by issuing approximately 80% of the new shares against contributions in kind (Expedeon shares).

Any new shares not subscribed by SYGNIS or Expedeon shareholders will be offered to select qualified investors in a private placement. Expected proceeds from the capital increase of up to EUR 5 million will be used for transaction-related expenses, including EUR 1.7 million cash payments to Expedeon shareholders, one-off integration costs and financing working capital. The transaction is subject to the approval by the Annual General Meeting on 20 June 2016.

Pilar de la Huerta, CEO and CFO of SYGNIS, commented: “In combining Expedeon and SYGNIS, we are creating a genomics and proteomics specialist with a broad product portfolio. Expedeon’s experienced international sales force will help us to execute on our international sales and commercialization strategy. Expedeon has OEM deals in place already with leading reagent companies worldwide, these existing channels will enhance the demand for SYGNIS products in the U.S. and Asian markets. Acquiring Expedeon will reduce the time to market for SYGNIS.”

“Expedeon is a profitable company with one third of its revenues coming from the U.S. market,” said de la Huerta. “Expedeon sales have increased each year over the past four years, driven by innovative and high margin products. We expect our joint pro-forma revenues for 2016 to exceed EUR 5 million, with strong upside potential in 2017. I very much look forward to working with the Expedeon team and making this transaction a success.”

Heikki Lanckriet, PhD, CEO of Expedeon, said: “SYGNIS and Expedeon share a vision of innovation and service by providing leading edge, patented genomics and proteomics tools to the scientific community. Our product lines are focused on complementary market segments, offering significant customer benefits. By joining forces with SYGNIS, we will be able to offer a wide variety of innovative products along the value chain and will have access to the international capital markets to effectively grow the business. We look forward to working with the SYGNIS team, exploiting our many market opportunities and meeting the new organization’s growth and profitability goals.”

SYGNIS will host a conference call (conducted in English) today at 14:00 Central European Time (CET), hosted by Pilar de la Huerta, CEO and CFO of SYGNIS, to discuss the planned acquisition of Expedeon.

Conference call details:

Time: 9 May 2016, 14:00 Central European Time (CET)

Interested parties can access the conference call via the following telephone numbers:

- From Germany: +49 (0) 69 7104 45598
- From Spain: +34 91 787 0777
- From the U.S.: +1 646 843 4608
- From the UK and other countries: +44 (0) 20 3003 2666

When prompted, please provide the password, “SYGNIS”.

The conference call, which is also being webcast, will be accompanied by a slide presentation which can be accessed during the call at: <https://mc-events.webex.com/mc-events/j.php?MTID=m6d1de463f2246857a9c4941756551e97>

Please dial in 5 minutes before the beginning of the event.

A conference call recording will be available in the "Investors" section of the Company's website at www.sygnis.com following the live call.

For further information on this transaction please also go to www.sygnis-merger.com.

For further information please contact:

SYGNIS AG

Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com

MC Services AG

Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu

About SYGNIS AG: www.sygnis.com

SYGNIS, headquartered in Germany and Spain, specializes in the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast-growing fields of molecular biology and next-generation sequencing applications. Key products include the TruePrime™ product line and SensiPhi®, licensed to a leading industry partner, for whole genome DNA amplification and sequencing, as well as the SunScript™ Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed on the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

About Expedeon Holdings Ltd.: <http://www.expedeon.com/about>

Expedeon Holdings Ltd. is privately held proteomics tools and reagents company headquartered in the UK. Expedeon is focused on providing high quality, simple and rapid solutions for protein research including RunBlue® gels for electrophoresis, the VersaWave spectrophotometer for quantitation or NVoy kits for refolding proteins to name just a few. Expedeon manufactures and sells a wide range of innovative, proprietary products through a direct sales force as well as well-established distribution channels. The company has manufacturing facilities in San Diego, California, USA and a representative office in Singapore.

This document is not a securities prospectus and the information contained herein does not constitute an offer to sell or a solicitation of an offer to purchase any securities of SYGNIS AG in the Federal Republic of Germany nor under any other jurisdiction, in particular not where such kind of offer or solicitation is prohibited or lacks the required permission. Potential investors in securities of SYGNIS AG are asked to familiarize themselves with and to observe the respective restrictions.

A decision to invest in the securities of SYGNIS AG should only be made on the basis of the securities prospectus detailing the public offering of securities of SYGNIS AG in the Federal Republic of Germany, which, subject to the approval of the German Federal Financial Supervisory Authority (BaFin) is anticipated to be published under www.sygnis.com/investors.

The information in this document may not be disseminated outside the Federal Republic of Germany in particular not in the United States, to U.S. Persons (as defined in regulation S of the U.S. Securities Act of 1933) or to publications with a general circulation in the United States with the exception of a such disclosures or announcements outside the Federal Republic of Germany which have to be made under the respective mandatory law. Any person who fails to comply with these restrictions may violate the security laws of certain jurisdictions, in particular of the United States. Securities in SYGNIS AG are not publicly offered outside the Federal Republic of Germany.

Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###